RSS Content

Allscripts Names Catherine Burzik to Board of Directors

Kinetic Concepts, Inc. CEO and former Johnson & Johnson, Kodak, and Applied Biosystems Executive Joins Board

CHICAGO, Oct. 27, 2011 /PRNewswire via COMTEX/ -- Allscripts (Nasdaq: MDRX) announced the appointment of Catherine Burzik, President and Chief Executive Officer of Kinetic Concepts, Inc. (KCI), to its Board of Directors. Burzik will add her unique experience to the Board and brings the number of directors to nine.

Ms. Burzik joined KCI in 2006 and has grown the company in revenue and profitability while doubling its market capitalization. KCI (NYSE: KCI) is a leading global medical technology company focused on advanced wound care, regenerative medicine, and therapeutic surfaces, all of which contribute to healing and improved outcomes for patients. Under Ms. Burzik's leadership, KCI moved into the regenerative medicine business by acquiring biotech company LifeCell in 2008. KCI reported revenue of $2.0 billion for 2010 and employs nearly 7,000 people worldwide.

Before leading KCI, Ms. Burzik served as President and previously as Chief Operating Officer of Applied Biosystems Group, a global provider of hardware, software and reagents to life scientists. She served as the Chief Executive Officer and President of Kodak Health Imaging Systems Inc., a subsidiary of Eastman Kodak Company, as well as its General Manager, Vice President, Corporate Marketing. She was also employed by Johnson & Johnson, where she served as the President of its Ortho-Clinical Diagnostics Inc. subsidiary from 1998 to 2003, and General Manager of its Critikon Inc. business from 1997 to 1998.

"Cathy Burzik has been a significant contributor to the growth and development of some of the world's best-known companies," said Glen Tullman, Chief Executive Officer of Allscripts. "Her years of leadership experience include a strong focus on operations and a unique ability to recognize the next chapter in healthcare technology, which will help Allscripts as we continue to broaden our business strategy."

Allscripts Chairman Phil Pead commented, "We are excited to welcome Cathy Burzik to our board. Her outstanding business track record, leadership and operational strengths will be of great value to our board and will help Allscripts stay at the forefront of client-driven innovation."

Ms. Burzik commented, "I'm delighted to serve on the Allscripts Board of Directors. I look forward to offering my perspective to help shape the strategic direction of Allscripts, a company that not only shares KCI's commitment to helping patients and providers through innovative new products, but connects them to each other and to the information and insights they need to deliver better outcomes."

Ms. Burzik serves as Director and Chairman Pro Tem for 2011 of the San Antonio branch of the Federal Reserve Board of Dallas. She also is Chairman of the Board of Trustees for Canisius College in Buffalo, NY; a Trustee of the Keck Graduate Institute Of Applied Life Sciences; and is a former director of Bausch & Lomb.

Ms. Burzik holds a BA Degree in Mathematics from Canisius College and an MA in Mathematics from the University of Buffalo and has taken post-graduate courses in software engineering and business management. She has also attended executive management programs at Penn State, Northwestern University's Kellogg School of Management and the Center for Creative Leadership.

She lives with her husband in San Antonio.

About Allscripts

Allscripts (NASDAQ: MDRX) provides innovative solutions that empower all stakeholders across the healthcare continuum to deliver world-class outcomes. The company's Electronic Health Record, Computerized Physician Order Entry and other clinical, financial, connectivity and information solutions for hospitals, physicians and post-acute organizations are the essential technologies that enable a Connected Community of Health(TM). To learn more about Allscripts, please visit http://www.allscripts.com/, Twitter, Facebook and YouTube.

FORWARD LOOKING STATEMENT

This press release contains forward-looking statements within the meaning of the federal securities laws. Statements regarding future events or developments, our future performance, as well as management's expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements with the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, some of which are outlined below. As a result, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on our results of operations or financial condition. Such risks, uncertainties and other factors include, among other things: the possibility that the expected synergies, efficiencies and cost savings of the merger with Eclipsys Corporation ("Eclipsys") will not be realized, or will not be realized within the expected time period; potential difficulties or delays in achieving platform and product integration and the connection and movement of data among hospitals, physicians, patients and others; the risk that the Allscripts and Eclipsys businesses will not be integrated successfully; competition within the industries in which we operate; failure to achieve certification under the Health Information Technology for Economic and Clinical Health Act could result in increased development costs, a breach of some customer obligations and could put us at a competitive disadvantage in the marketplace; the volume and timing of systems sales and installations, the length of sales cycles and the installation process and the possibility that our products will not achieve or sustain market acceptance; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; competitive pressures including product offerings, pricing and promotional activities; our ability to establish and maintain strategic relationships; undetected errors or similar problems in our software products; the outcome of any legal proceeding that has been or may be instituted against us; compliance with existing laws, regulations and industry initiatives and future changes in laws or regulations in the healthcare industry, including possible regulation of our software by the U.S. Food and Drug Administration; the possibility of product-related liabilities; our ability to attract and retain qualified personnel; the implementation and speed of acceptance of the electronic record provisions of the American Recovery and Reinvestment Act of 2009; maintaining our intellectual property rights and litigation involving intellectual property rights; risks related to third-party suppliers and our ability to obtain, use or successfully integrate third-party licensed technology; and breach of our security by third parties. See our Annual Report on Form 10-KT for the seven months ended December 31, 2010 and other public filings with the SEC for a further discussion of these and other risks and uncertainties applicable to our business. The statements herein speak only as of their date and we undertake no duty to update any forward-looking statement whether as a result of new information, future events or changes in expectations.

SOURCE Allscripts Healthcare Solutions, Inc.

Stock Information

Featured Events

  Earnings Press Release

  Q1 Supplemental Financial Data